OPA1 and ovarian carcinoma: Further supporting the concept of differential drug sensitivity, the study also showed that OPA1 or DNML1 deletion in the MCAS ovarian carcinoma cell line causes sensitization to BCL-2 and MCL-1 inhibitors but not to apoptosis-inducing etoposide [168].